CJC-1295 + Ipamorelin
The most studied growth hormone secretagogue combination in endocrine research. These two compounds act through separate receptor systems — one stimulating, one amplifying — producing an additive effect documented in published neuroendocrine studies.
How It Works
The Target
Two complementary points in the growth hormone axis: GHRH receptors (CJC-1295) and Ghrelin/GHS receptors (Ipamorelin) on pituitary somatotroph cells.
The Mechanism
CJC-1295 has a Drug Affinity Complex (DAC) modification that allows it to bind albumin in the bloodstream, extending its half-life from minutes to days. It stimulates GH production. Ipamorelin triggers GH release from stored vesicles. Together, they increase both the production and release of growth hormone while preserving natural pulsatile patterns.
Why It Matters
Ipamorelin is notable for being the first truly selective GH secretagogue — it triggers GH release without significantly affecting cortisol, prolactin, or other hormones. Combined with CJC-1295's extended duration, this pairing provides sustained, clean GH elevation.
Specifications
| Purity | >=98% each |
| MW | CJC-1295: ~3.3 kDa; Ipamorelin: ~0.7 kDa |
| Form | Lyophilized blend |
| Storage | -20 degrees C |
| Reconstitution | Bacteriostatic water |
| Shelf Life | 24 months |
Published References
Read the full CJC-1295 + Ipamorelin research article →